Inzolfi

Fingolimod, the active ingredient in Inzolfi, is a sphingosine‑1‑phosphate receptor modulator presented as an oral formulation for oral use. It is indicated for relapsing forms of multiple sclerosis and works by retaining lymphocytes in lymph nodes, thereby reducing inflammatory activity in the central nervous system.

GNH USA supplies Inzolfi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inzolfi acts on the sphingosine‑1‑phosphate pathway to modify disease activity in multiple sclerosis.

- Relapsing‑remitting multiple sclerosis: reduces the frequency of clinical relapses and slows disability progression. - Active secondary progressive multiple sclerosis: decreases relapse rate and may delay worsening of disability. - Clinically isolated syndrome: lowers the risk of conversion to clinically definite multiple sclerosis.

Fingolimod is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: usually transient. - Nausea: may occur early in treatment. - Fatigue: common during the first weeks. - Upper respiratory tract infection: mild symptoms. - Elevated liver enzymes: monitored via laboratory tests.

Serious or Rare Side Effects: - Infections: opportunistic or severe bacterial infections. - Cardiac arrhythmias: bradycardia or atrioventricular block, especially after first dose. - Macular edema: visual disturbances requiring ophthalmologic assessment. - Severe liver injury: marked transaminase elevation. - Progressive multifocal leukoencephalopathy (PML): rare but life‑threatening. - Malignancies: increased incidence of certain cancers reported.

Before initiating Fingolimod, clinicians should assess baseline parameters and educate patients about potential risks.

- Lymphocyte monitoring: check absolute lymphocyte count before start and periodically thereafter. - Liver function: obtain baseline liver enzymes and repeat during therapy. - Cardiac evaluation: perform ECG and monitor heart rate after the first dose. - Infection risk: advise patients to report signs of infection promptly and avoid live vaccines. - Pregnancy and lactation: discuss potential risks and advise contraception during treatment. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Fingolimod can interact with several drug classes, influencing safety and efficacy.

Major Interactions (Avoid): - Concurrent immunosuppressants: may amplify immunosuppression and infection risk. - Live vaccines: can cause uncontrolled infection due to impaired immunity. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase Fingolimod plasma levels.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may modestly raise drug exposure. - Antihypertensive agents (especially beta‑blockers): additive bradycardia effect after first dose. - Antiplatelet or anticoagulant therapy: heightened bleeding tendency if liver enzymes rise. - Vaccines (non‑live): monitor immune response effectiveness.